|Bid||2.4000 x 4000|
|Ask||2.3900 x 900|
|Day's Range||2.3100 - 2.5100|
|52 Week Range||0.9900 - 2.6700|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Subscribe to Yahoo Finance Plus to view Fair Value for GERN
FOSTER CITY, Calif., August 04, 2022--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 4:30 p.m. ET the same day.
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
FOSTER CITY, Calif., August 03, 2022--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.